Protocol Ledger

NCT06616025 · Phase III · RECRUITING

This Study Will Evaluate the Effectiveness of NTX-001, a Surgical Nerve Repair Product When Used in People With Upper Extremity Nerve Lacerations.

Interventional Phase III clinical trial protocol NCT06616025 sponsored by Neuraptive Therapeutics in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-02-10 Enrollment: 98 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06616025
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)98 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06616025
Protocol FieldVerified Registry Value
NCT IdentifierNCT06616025
Consolidated Lead SponsorNeuraptive Therapeutics
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment98 participants (ESTIMATED)
Registered Start Date2025-02-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06616025
Hospital Research SiteLocationSite Profile
Cedars-Sinai Medical CenterLos Angeles, CAOpen Hospital Dossier ->
UCSF Medical Center and Helen Diller Cancer CenterSan Francisco, CAOpen Hospital Dossier ->
University of Chicago MedicineChicago, ILOpen Hospital Dossier ->
University of LouisvilleLouisville, KYOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI